〇f the 112 down-regulated Smoothened Agonist clinical trial genes, 81 have a miR-106b binding site and 31 have a perfect 8-mer binding site. The average number of seeds per targeted gene is 1. 73. Fold-change ranged from +1. 15 to +1. 47 for upregulated genes and −1. 16 to −2. 22 for down-regulated genes. Some of the notable differentially

expressed targets determined by RNA-Seq include the known targets retinoblastoma 1 and IL8, and also novel targets Kruppel-like factor-2 (KLF2) and KLF6, and pleckstrin and Sec7 domain-containing 3. By transfecting cells with miR-106b or LNA followed by treatment with the death ligand TRAIL, we were able to detect a subtle but significant difference in resistance to apoptosis. Percentages of apoptotic nuclei were compared between treatments and were 41. 7% for miR-106b and 56. 4% for LNA in Mz-ChA-1 cells (p<0. 05). Similarly, miR-106b protected H69 cells against apoptosis, with 10. 7% apoptotic nuclei for miR-106b-treated

and 23. 1% for LNA-treated cells (p<0. 01). Published reports indicate a positive effect of miR-106b on proliferation; however, using a MTT assay, we found no significant difference over a 72-hour KU-57788 manufacturer time course. The unexpected absence of increased proliferation by miR-1 06b suggests a cell-type specific function, whereby CCA cells are not reliant on miR-106b for proliferation. Our genome-wide analysis has identified novel and previously unpredicted targets of interest, particularly the tumor suppressors KLF2 and KLF6 which may be of future importance. Conclusions: miR-1 06b represents a functional target whose repression may improve sensitivity to apoptosis in CCA. Disclosures: The following people have nothing to disclose: Cody J. Wehrkamp, Mary A. Smith, Sathish Kumar Natarajan, Sanjit Pandey, Chittibabu Guda, Justin L. Mott The HGF receptor MET and the EGF receptor (EGFR) are mitogenic receptor-tyrosine kinases for hepatocytes. The MET-EGFR signaling pathway is activated within 15-30 minute following a two-thirds medchemexpress partial hepatectomy (PHx) in mice and rats. MET and EGFR functionally interact and there is

also considerable crosstalk between the two pathways. In order to understand the role played by these two pathways during liver regeneration, we used MET-EGFR specific Tyrosine kinase inhibitors to block the receptor kinase activity. Mice were administered EGFR specific Gefitinib (300 mg/kg) and MET specific JNJ 38877605 (100mg/kg) by oral gavages. The following day, mice were administered a second dose and two hours later a PHx was carried out. Appropriate vehicle controls were also used. In mice treated with Tyrosine kinase inhibitors, pMET & pEGFR levels were significantly reduced compared to vehicle treated controls. Global changes in gene expression patterns in treated and control livers were analyzed by microarray analyses.